Exact Sciences stock (US30063P1057): Diagnostics peer update after Petrichor hiring
Exact Sciences is gaining renewed market attention after its former CEO, Don Hardison, joined Petrichor as an operating partner. While not a direct company action, this move highlights the company's past leadership and the broader diagnostics sector, where sentiment is driven by reimbursement, test adoption, and commercial execution. Investors are encouraged to monitor future company-reported results and guidance for more significant insights rather than indirect industry headlines.
Exact Sciences stock (US30063P1057): screening business, oncology focus, and what U.S. investors are
Exact Sciences is a U.S. diagnostics company primarily known for its Cologuard colorectal cancer screening test and oncology-focused molecular testing. The company's investment appeal lies in the large addressable market for colorectal cancer screening and its diversified oncology segment. Investors are keenly watching the company's commercial execution, test adoption rates influenced by reimbursement and guidelines, and its ability to achieve sustainable profitability in the competitive diagnostics landscape.
Exact Sciences Corp. stock (US30063P1057): diagnostics specialist in focus after leadership news
Exact Sciences Corp., known for its Cologuard colorectal cancer screening test, is gaining renewed attention after its former CEO, Don Hardison, joined healthcare investor Petrichor. The company's business model focuses on developing and commercializing diagnostic tests for early cancer detection and precision oncology, with Cologuard being a primary revenue driver. Exact Sciences operates in a competitive and evolving diagnostics market, making its ability to innovate and navigate policy changes crucial for future performance.
Exact Sciences Corp. stock (US30063P1057): earnings backdrop and cancer diagnostics focus
Exact Sciences Corp. is drawing investor attention after its latest quarterly update, which highlighted continued growth in colorectal cancer screening revenue from its Cologuard product. The company operates in the molecular diagnostics sector, focusing on cancer detection and early screening, and is investing heavily in broader cancer diagnostics despite ongoing operating losses due to high research and marketing spending. The article also discusses market trends, competitive positioning, and risks for investors.
Exact Sciences Corp stock (US30063P1057): acquisition plans stir debate around growth and dilution
Exact Sciences Corp is set to acquire Abbott’s molecular diagnostics unit, a move that will expand its testing portfolio to include infectious disease and genetic testing alongside its current cancer diagnostics. While this acquisition broadens market reach and leverages existing infrastructure, it also introduces near-term earnings dilution and integration risks. Investors will be closely watching how the company manages these challenges and ultimately realizes the synergies from this strategic expansion.
Exact Sciences stock (US30063P1057): latest business update and investor focus
Exact Sciences remains a key company for US investors due to its focus on cancer screening and diagnostics, particularly in the colorectal cancer market. The company's performance is tied to test adoption, reimbursement coverage, and competitive execution. Investors monitor quarterly reports, payer decisions, and product rollouts for future catalysts, as its business model is strongly influenced by public health trends and commercial strategies.
Exact Sciences stock (US30063P1057): Screening leader faces a new investor test
Exact Sciences remains a significant diagnostics company for U.S. investors, primarily due to its leading colorectal cancer screening product, Cologuard. The company's future performance hinges on consistent adoption rates, stable reimbursement policies, and its ability to expand beyond its current product range. Investors are advised to monitor quarterly execution, test volume trends, and any updates to its growth projections.
Exact Sciences Corp. stock (US30063P1057): earnings beat and Abbott takeover reshape cancer diagnost
Exact Sciences Corp. reported stronger-than-expected quarterly results and has agreed to a multi-billion dollar takeover by Abbott, valued at around $21 billion. This acquisition is set to strengthen Abbott's cancer diagnostics portfolio and integrate Exact Sciences' molecular tests into Abbott's global distribution network. While Exact Sciences has strong growth prospects in colorectal cancer screening and precision oncology, it still operates with negative net margins, with the stock's performance driven by revenue growth and strategic value rather than current income.
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B
Exact Sciences Corp., a cancer screening technology leader, was acquired by Abbott Laboratories for $20.6 billion, consolidating control over the U.S. cancer screening market. The deal, completed on March 23, 2026, followed Exact Sciences missing its consensus EPS estimates in its latest quarterly earnings report, despite significant revenue growth. This acquisition highlights strategic shifts in the diagnostics sector and offers investors a potentially stable, defensive investment in healthcare.
Exact Sciences stock (US30063P1057): Q1 2026 revenue growth driven by Cologuard and Oncotype DX
Exact Sciences reported a strong Q1 2026 with $1.62 billion in revenue, marking a 12% year-over-year increase. This growth was primarily fueled by the robust performance of its cancer screening product, Cologuard, and its diagnostic test, Oncotype DX. The company is actively investing in pipeline expansion and strengthening its cash position to further its market share in the precision oncology diagnostics sector.
Exact Sciences Corp. stock (US30063P1057): Risk channels signal institutional focus
Exact Sciences Corp. (EXAS) stock is being driven by institutional models through its price action, influencing risk channels and allocation strategies. The company, known for its Cologuard cancer screening test, plays a significant role in US healthcare spending and preventive diagnostics. Its strong market position in colorectal cancer screening and expansion into other areas make it relevant for growth-oriented US investors.
Exact Sciences Corp. stock (US30063P1057): Q1 2026 earnings and screening advancements
Exact Sciences Corp. reported strong Q1 2026 financial results, with revenue reaching $1.62 billion, a 12% year-over-year increase, driven by Cologuard and Oncotype DX. The company's commitment to expanding non-invasive cancer screening, particularly with Cologuard Plus, continues to drive growth. These results highlight Exact Sciences' strong position in the precision oncology diagnostics sector, appealing to US investors.
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue up 23%
Exact Sciences Corp. reported a Q4 earnings miss, with earnings per share at -$0.21 against an estimated $0.08, but showed strong revenue growth of 23.1% year-over-year. The growth was driven primarily by its Cologuard product, a non-invasive colorectal cancer screening test, which accounts for over 80% of sales. Despite increased investments and an earnings miss, the company's focus on precision medicine and potential for market expansion in the US cancer screening market positions it as a significant player for investors.
Exact Sciences Corp. stock (US30063P1057): Q4 earnings miss with revenue growth
Exact Sciences Corp. reported Q4 earnings of -$0.21 per share, missing analyst estimates by $0.29, despite a 23.1% year-over-year revenue increase. The company, known for its Cologuard cancer screening test, demonstrates continued product adoption and R&D investment in the high-growth molecular diagnostics sector. While facing profitability challenges with a net margin of -6.40%, its market leadership in colorectal cancer screening and focus on early detection position it as a key player in the US healthcare market for investors.
Exact Sciences Corp. stock (US30063P1057): Q4 2025 earnings miss on EPS despite revenue beat
Exact Sciences Corp. reported its Q4 2025 earnings, missing EPS estimates with -$0.21, despite revenue rising 23.1% year-over-year to $878.38 million and beating forecasts. The company continues to show strong top-line growth driven by its cancer-screening portfolio, particularly Cologuard, while analysts anticipate a return to profitability in the next year. Exact Sciences, with a market cap of $20.03 billion, remains a growth-oriented healthcare stock with significant R&D investments.
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover
This article mentions that Exact Sciences (EXAS) stock fell in premarket trading despite analysts suggesting it could be a triple-digit acquisition target for Abbott (ABT). It notes that Baird reiterated an Outperform rating and $125 price target on EXAS after its earnings. The article also provides a brief overview of year-to-date performance for both companies.
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits
Exact Sciences Corporation (EXAS) stock hit a four-year high despite multiple Wall Street downgrades following its agreement to acquire Abbott Labs' Molecular Diagnostics business. The market's positive reaction to the acquisition, seen as a strategic move to boost revenue and improve market position, has led to significant gains for investors. Retail traders, however, appear to be taking profits, suggesting a potential short-term pullback after the surge.
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits
Exact Sciences stock reached a four-year high despite multiple downgrades from Wall Street analysts following its deal with Abbott. The stock's rise was attributed to optimism surrounding the Abbott deal, though retail traders reportedly took profits, leading to a slight dip. Analysts are cautious, citing potential competitive pressures and the terms of the Abbott diagnostic device deal.
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account
Representative Laura Friedman recently exchanged shares of Exact Sciences Corp for Abbott Laboratories through her Fidelity brokerage account. The transaction, valued between $1,001 and $15,000, was a result of a merger. Abbott Laboratories is currently viewed as undervalued by InvestingPro.
Laura Friedman trades Exact Sciences for Abbott Laboratories in brokerage account
Laura Friedman, representative for California's 30th congressional district, recently exchanged shares of Exact Sciences Corp (NASDAQ:EXAS) for Abbott Laboratories (NYSE:ABT) via her Fidelity brokerage account. The transaction, valued between $1,001 and $15,000, occurred due to a merger. Abbott Laboratories, a global healthcare company, is noted as potentially undervalued by InvestingPro analysis, despite the financial details and reasons behind Friedman's specific decision remaining undisclosed.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?
Exact Sciences Corp. leads the non-invasive cancer screening market with its Cologuard test, targeting colorectal cancer. The company's business model relies on widespread adoption and reimbursement, positioning it as a key player in preventive healthcare amidst increasing cancer rates globally. While analysts are generally positive due to strong clinical data and market leadership, investors should consider risks like reimbursement uncertainties, competition, and high R&D costs when evaluating its long-term growth potential and market valuation.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock sustained upside?
Exact Sciences Corp. leads the non-invasive cancer screening market, primarily with its Cologuard test, targeting a significant U.S. population for colorectal cancer detection. The company's business model relies on specialized diagnostics and recurring revenue from insurance-reimbursed lab services. While analysts generally hold a positive outlook due to strong clinical data and market adoption, investors should monitor risks such as reimbursement changes, R&D costs, and competition from emerging technologies.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?
Exact Sciences Corp. (US30063P1057) is a leader in non-invasive cancer screening, with its Cologuard product dominating colorectal cancer detection. The company's business model relies on recurring revenue from high-volume, non-invasive tests and strategic investments in automation. While Cologuard addresses a significant market, the company is also expanding into multi-cancer detection with products like CancerSEEK, targeting a broader oncology screening market.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening dominance strong enough to unlock new upside?
Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship Cologuard product dominating colorectal cancer detection. The company's business model relies on high-volume, non-invasive tests and aims to capture a larger share of the multi-billion-dollar U.S. cancer screening market. While it faces risks from reimbursement changes and competition, analysts remain positive due to Cologuard's strong adoption and pipeline potential, especially in multi-cancer detection.
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Abbott Laboratories shares fell 3.2% despite marginally beating Wall Street's profit and revenue estimates for the first quarter. The decline was largely due to a lowered 2026 earnings outlook, impacted by the recently completed $23 billion acquisition of Exact Sciences for oncology diagnostics. While the acquisition establishes Abbott as a leader in a high-growth segment, it is expected to dilute near-term earnings by about $0.20 per share.
Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition
Abbott (ABT) reported Q1 2026 net sales of $11.164 billion, up 7.8% year over year, with adjusted diluted EPS rising 6% to $1.15, despite GAAP earnings declining due to acquisition-related charges. The company completed its acquisition of Exact Sciences, forming a new Cancer Diagnostics business, and provided updated full-year 2026 guidance, including a projected comparable sales growth of 6.5%–7.5%. Abbott also declared its 409th consecutive quarterly dividend of $0.63 per share.
Q1 progress positions Abbott for accelerating growth in 2026
Abbott announced strong first-quarter 2026 results, achieving its EPS target and completing the acquisition of Exact Sciences. The company's growth is driven by its new cancer diagnostics business, medical devices, and established pharmaceuticals, positioning it for accelerating growth throughout the year with updated full-year guidance and productive pipeline progress in structural heart and diabetes care. Abbott also provided detailed financial data and information on its medical products, including the Amplatzer Amulet, FreeStyle Libre 3, Cancerguard, and Cologuard.
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag
Abbott Laboratories' shares fell despite beating initial earnings and revenue estimates, primarily due to the dilutive effect of its recent $23 billion acquisition of Exact Sciences, a cancer diagnostics company. While the acquisition positions Abbott as a leader in oncology diagnostics, it will weigh on near-term earnings, leading to a revised 2026 adjusted diluted EPS outlook of $5.38 to $5.58, down from a previous range of $5.55 to $5.80. The company anticipates a $0.20 dilution from the deal but remains confident in its accelerating growth trajectory for the year.
Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus
Exact Sciences Corp. is a leader in non-invasive cancer screening, particularly with its flagship product Cologuard for colorectal cancer. The company's focus on early detection, expanding into multi-cancer screening, and strong market penetration in the U.S. and other English-speaking markets make it a compelling investment. Analysts view Exact Sciences favorably due to its growth potential, reimbursement stability, and strategic partnerships, despite risks like competition and regulatory changes.
Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus
Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship product Cologuard revolutionizing colorectal cancer detection. The company's expansion into multi-cancer detection and strategic partnerships position it for continued growth in the diagnostics sector. Investors in the United States and English-speaking markets are focusing on Exact Sciences due to its potential in preventive diagnostics and strong market positioning.
Exact Sciences Corp. stock (US30063P1057): Is its cancer screening push strong enough for U.S. inves
Exact Sciences Corp., listed on Nasdaq under EXAS, is a leader in non-invasive cancer screening with products like Cologuard and the Oncotype DX portfolio. The company's strategy focuses on molecular diagnostics, recurring revenue streams from return testing, and expanding into multi-cancer detection, aligning with growing U.S. healthcare demands for early detection. While analysts see it as a growth leader, potential risks include reimbursement cuts, competition from other blood tests, and operational capacity constraints.
EXAS Technical Analysis & Stock Price Forecast
The article provides a technical analysis for Exact Sciences Corp (EXAS), indicating a "Strong Buy" overall consensus based on aggregated technical signals. It details various indicators like RSI, MACD, and moving averages, along with key support and resistance levels. Despite some sell signals from momentum oscillators like RSI and Stochastic, the stock is trading above its key moving averages, suggesting a bullish trend.
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now
Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively for long-term growth.
Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now
Abbott Laboratories completed its $23 billion acquisition of Exact Sciences on March 23, 2026, integrating Exact Sciences' cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics division. This acquisition positions Abbott in the growing $60 billion U.S. cancer screening market, offering North American investors exposure to diversified revenue and reduced single-product risk. Analysts view the deal positively, expecting it to be accretive long-term despite near-term EPS dilution, with upcoming Q1 2026 earnings acting as a key checkpoint for integration and growth.
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026?
Exact Sciences stock has seen a post-earnings slide, but the company's core Cologuard franchise continues to grow, and profitability is becoming clearer. The article examines the fundamental changes, Wall Street's sentiment, and how US investors might position themselves for 2026. It highlights the company's strong revenue growth, improving margins, and robust cash position, despite ongoing unprofitability on a GAAP basis, making it a risk-reward test for high-growth healthcare investors.
Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History
This article from GuruFocus.com, titled "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History," provides historical holding information for Exact Sciences Corp (EXAS) within the Select Health Care Portfolio. The content is primarily a navigation-heavy page from a financial data website, indicating where users can find such data and related investment tools. It does not provide direct analysis or details of the holding history itself, but rather signposts the availability of such information on the platform.
EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
EXACT Sciences Corp., a Pharmaceuticals & Biotechnology company, has received a mixed stock evaluation with varying technical indicators. Despite this, the company has significantly outperformed the S&P 500 over both the past year and decade, demonstrating strong resilience and stock performance recovery. Key technical indicators show both bullish and bearish signals across different timeframes.
Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares
The Vanguard Group has reported 0 shares of Exact Sciences (NASDAQ: EXAS) common stock, representing 0% ownership, following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing emphasizes that this reclassification is a reporting change, not an indication of a sale.
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update
Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks like competition and potential reimbursement cuts remain.
Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update
Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seeking exposure to this sector, though competition and regulatory risks remain.
Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist
Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.
Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026
Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.
Abbott completes Exact Sciences acquisition
Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.
Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening
Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and drive future development of preventative and personalized diagnostic tools.
Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing
Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.
Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges
Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a "Moderate Buy" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Switzerland and the alignment with precision medicine trends.
The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout
Walgreens has partnered with Exact Sciences for a nationwide rollout of the Cologuard colorectal cancer screening test through its pharmacies, which could significantly impact Exact Sciences' growth. While this expansion addresses care gaps and diversifies screening access, investors should also consider Exact Sciences' historical cash burn and dependence on Cologuard, despite new data on its Oncodetect and Cancerguard tests. The company's investment narrative projects substantial revenue and earnings growth by 2028, with fair value estimates aligning with or exceeding its current price.
Exact Sciences (NASDAQ: EXAS) secures approvals as Abbott merger targets March 23 close
Exact Sciences has announced that all regulatory approvals and clearances for its merger with Abbott Laboratories have been obtained. Stockholders previously approved the transaction on February 20, 2026, and the merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions. Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.
Abbott to close $21B Exact Sciences acquisition Monday
Abbott is set to finalize its $21 billion acquisition of Exact Sciences on Monday, having received all necessary regulatory clearances. This strategic move is expected to significantly bolster Abbott's presence in cancer screening and diagnostics, adding a new platform and an estimated $3 billion in incremental sales by 2026. Exact Sciences is known for its Cologuard test and other molecular cancer detection technologies, which Abbott anticipates will help reach millions more people for early cancer detection and management.
Exact Sciences to be acquired by Abbott after receiving all regulatory approvals; closing anticipated March 23, 2026
Exact Sciences announced that all regulatory approvals for its merger with Abbott have been received, with the transaction expected to close on March 23, 2026. This merger will make Exact Sciences a direct, wholly owned subsidiary of Abbott, following shareholder approval and regulatory clearance obtained on March 19, 2026. The closing is subject to remaining conditions and customary risks.
